CN117187206A - Fucosyltransferase from intestinal microorganisms and application thereof - Google Patents
Fucosyltransferase from intestinal microorganisms and application thereof Download PDFInfo
- Publication number
- CN117187206A CN117187206A CN202310567618.5A CN202310567618A CN117187206A CN 117187206 A CN117187206 A CN 117187206A CN 202310567618 A CN202310567618 A CN 202310567618A CN 117187206 A CN117187206 A CN 117187206A
- Authority
- CN
- China
- Prior art keywords
- fucosyltransferase
- gene
- recombinant
- fermentation
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019236 Fucosyltransferases Proteins 0.000 title claims abstract description 58
- 102000006471 Fucosyltransferases Human genes 0.000 title claims abstract description 51
- 244000005700 microbiome Species 0.000 title abstract description 18
- 230000000968 intestinal effect Effects 0.000 title abstract description 17
- 238000000855 fermentation Methods 0.000 claims abstract description 54
- 230000004151 fermentation Effects 0.000 claims abstract description 54
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 45
- 241000894006 Bacteria Species 0.000 claims abstract description 32
- 241000194108 Bacillus licheniformis Species 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 229940062827 2'-fucosyllactose Drugs 0.000 claims abstract description 6
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims abstract description 6
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims abstract description 6
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000013612 plasmid Substances 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 13
- 101150088678 manB gene Proteins 0.000 claims description 6
- 101100075927 Aspergillus aculeatus mndA gene Proteins 0.000 claims description 5
- 101100280818 Escherichia coli (strain K12) fcl gene Proteins 0.000 claims description 5
- 101100022282 Escherichia coli O157:H7 manC2 gene Proteins 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 101150032120 manC gene Proteins 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 108090000992 Transferases Proteins 0.000 claims description 4
- 108030006298 GDP-L-fucose synthases Proteins 0.000 claims description 3
- 108010062427 GDP-mannose 4,6-dehydratase Proteins 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 101150106565 gmd gene Proteins 0.000 claims 2
- GBXZONVFWYCRPT-KVTDHHQDSA-N [(2s,3s,4r,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl] dihydrogen phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C=O)OP(O)(O)=O GBXZONVFWYCRPT-KVTDHHQDSA-N 0.000 claims 1
- 235000013350 formula milk Nutrition 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 abstract description 11
- 235000020256 human milk Nutrition 0.000 abstract description 7
- 210000004251 human milk Anatomy 0.000 abstract description 7
- 229920001542 oligosaccharide Polymers 0.000 abstract description 7
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 7
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 34
- 108090000790 Enzymes Proteins 0.000 description 34
- 229940088598 enzyme Drugs 0.000 description 34
- 239000000243 solution Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 238000012258 culturing Methods 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000011324 bead Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000002156 mixing Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000010276 construction Methods 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 101100272609 Arabidopsis thaliana BLH1 gene Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 101150046686 LAP3 gene Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 241000311115 Bacillus paralicheniformis ATCC 9945a Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 108700040099 Xylose isomerases Proteins 0.000 description 3
- -1 arsinic acid salt-hydrochloric acid Chemical compound 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000007885 magnetic separation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 2
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- VZZBCNXVZFAIQX-UHFFFAOYSA-N bms-986260 Chemical compound ClC=1C=C(C=CC=1F)C=1N=CN(C=1C=1C=CC=2N(N=1)C(=CN=2)C#N)CCO VZZBCNXVZFAIQX-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Abstract
The invention discloses fucosyltransferase from intestinal microorganisms and application thereof, belonging to the technical fields of synthetic biology and genetic engineering. The invention provides a fucosyltransferase with alpha-1, 2 specificity screened from intestinal microorganisms and a coding gene thereof, the coding genes of the fucosyltransferase are heterologously expressed in bacillus licheniformis by utilizing a gene recombination technology, and the obtained recombinant strain can be used for fermentation production of 2' -fucosyllactose. The fucosyltransferase has high catalytic activity, and has great potential in applications such as fermentation production of breast milk oligosaccharide when the optimal catalytic temperature is matched with high-temperature fermentation of bacteria.
Description
Technical Field
The invention relates to fucosyltransferase from intestinal microorganisms and application thereof, belonging to the technical fields of synthetic biology and genetic engineering.
Background
The breast milk oligosaccharide is an important oligosaccharide only existing in breast milk, and plays an irreplaceable role in promoting the growth of intestinal flora of infants, improving the function of an immune system, promoting the development of brains and the like. Wherein 2 '-fucosyllactose (2' -FL) accounts for 30% of total amount of breast milk oligosaccharides, and is one of the highest ratio. It can be synthesized from L-fucose and lactose by the catalysis of fucosyltransferase.
In recent years, researchers have begun to widely use microbial fermentation methods to produce 2' -FL, with the host bacteria used primarily including E.coli, B.subtilis, B.licheniformis, and the like. The wild-type genome of these microorganisms already contains various enzymes of the 2' -FL synthesis pathway, such as mannomutase, mannose-1-phosphate-guanylate transferase, etc., but none of them has fucosyltransferase. The most widely used fucosyltransferase genes in the construction of 2' -FL recombinant strains at present are FutC derived from helicobacter pylori and wbgL derived from Escherichia coli O126. Although recombinant bacteria capable of producing 2' -FL have been obtained by the construction of fucosyltransferases derived from the above two microorganisms, the fucosyltransferases encoded by futC and wbgL have extremely low catalytic efficiency at temperatures above 40 ℃. The high-temperature fermentation of industrial microorganisms is very beneficial to reducing the risk of bacteria contamination, improving the fermentation efficiency and reducing the fermentation cost, so that the fucosyltransferase which has high catalytic efficiency and optimal catalytic temperature matched with the high-temperature fermentation conditions of bacteria has great potential in the applications of 2' -FL fermentation production and the like.
Intestinal microorganisms are a class of microorganisms that have important interactions with breast milk oligosaccharides, and the hydrolysis or transglycosylation reactions mediated by enzymes produced by them can alter the structure of breast milk oligosaccharides. Thus, intestinal microorganisms are likely to be a source of novel glycosyltransferases. However, intestinal microorganisms are mostly difficult to perform pure culture and isolation under in vitro standard conditions, which hinders the screening of high catalytic efficiency and high temperature resistant fucosyltransferases from intestinal microorganism sources.
Disclosure of Invention
Aiming at the technical problems of lack of high catalytic efficiency and high temperature resistance of fucosyltransferase and difficulty in screening, the invention aims to provide fucosyltransferase with high catalytic activity of intestinal microorganisms and optimal catalytic temperature matched with high-temperature fermentation of bacteria and encoding gene thereof by utilizing a metagenomic technology. The novel enzyme screened by the detection of the fermentation and the metabolite detection of the recombinant microorganism carrying the gene can be efficiently synthesized into 2' -FL at 42 ℃, thereby having great potential in the applications such as fermentation production of breast milk oligosaccharide.
The invention provides a fucosyltransferase with alpha-1, 2 specificity from intestinal microorganisms, wherein the amino acid sequence of the fucosyltransferase is shown as SEQ ID NO.1 and named as HM3.
The invention provides a coding gene of fucosyltransferase with alpha-1, 2 specificity from intestinal microorganisms, wherein the coding gene of fucosyltransferase is obtained by screening from intestinal metagenome; the nucleotide sequence for encoding HM3 is shown as SEQ ID NO. 2;
the recombinant bacterium for expressing the fucosyltransferase provided by the invention takes bacteria or yeast as a host to express the fucosyltransferase.
In one embodiment of the invention, the host is bacillus licheniformis.
The construction method of the recombinant bacterium BLM2 for expressing the fucosyltransferase HM3, provided by the invention, comprises the following steps:
by homologous weightThe group has nucleotide sequence shown as P shown in SEQ ID NO.3 Lan The promoter and terminator ter of xylose isomerase gene with nucleotide sequence shown as SEQ ID NO.4 are respectively fused with mannose mutase gene manB shown as SEQ ID NO.5, mannose-1-phosphate-guanylate transferase gene manC shown as SEQ ID NO.6, GDP-mannose-4, 6-dehydratase gene gmd shown as SEQ ID NO.7, GDP-L-fucose synthase gene wcaG shown as SEQ ID NO.8 and fucosyltransferase gene HM3 to obtain corresponding gene expression fragments which are respectively named as H1, H2, H3, H4 and M5;
the primer pairs are used for amplifying gene expression fragments H1, H2, H3, H4 and M5 respectively, so that enzyme cutting sites are introduced at two ends of the gene fragments. And sequentially connecting the gene expression fragments H1, H2 and H3 into pHY300PLK plasmid by using a homologous recombination method to obtain recombinant plasmid pHY-H123. Then sequentially connecting gene expression fragments H4 and M5 into pHT43 plasmid by using a homologous recombination method to obtain recombinant plasmid pHT-M45, and further verifying the construction condition of the plasmid by using 1% agarose gel electrophoresis;
converting the successfully constructed recombinant plasmid pHYH123 into bacillus licheniformis ATCC 9945A to obtain bacillus licheniformis engineering bacteria BLH1, and converting the recombinant plasmid pHT-M45 into bacillus licheniformis engineering bacteria BLH1 by the same method to obtain recombinant bacillus licheniformis bacteria BLM2;
the method for producing 2' -fucosyllactose by recombinant bacteria expressing fucosyltransferase comprises streak-activating the recombinant bacteria on an LB plate, culturing at 37 ℃ for 16h, selecting single colony, inoculating in 15mL LB culture medium at 37 ℃ for 250 r.min -1 Culturing for 16-18 h as seed solution, transferring 1mL of seed solution into 30mL of shake flask fermentation medium, shake flask fermenting, controlling initial OD to 0.5-1, and culturing at 37deg.C or 42deg.C for 250r min -1 Culturing;
or subjecting the recombinant strain to fed-batch fermentation in a fermenter at a fermentation temperature of 42 ℃ and an initial pH of 7.5. When the pH in the fermentation process is reduced to 7.0, the pH in the fermentation process is maintained at about 7.0 by adding 50% ammonia water, the aeration rate in the fermentation process is controlled at 0.5vvm, the DO is controlled at about 30% by coupling stirring and DO, and the upper limit of the rotating speed is set at 800rpm. Sucrose was continuously fed after 8h fermentation, maintaining it unconsumed.
In one embodiment of the invention, the use of intestinal metagenome-derived fucosyltransferases and recombinant bacteria expressing fucosyltransferases in the production of 2' -FL fermentation production is presented.
The invention has the beneficial effects that:
(1) The invention provides a novel fucosyltransferase HM3 from intestinal microorganisms, which has high catalytic efficiency and good catalytic function under high-temperature fermentation (42 ℃), and is beneficial to reducing the risk of bacteria contamination, improving the fermentation efficiency and reducing the fermentation cost in industrial application.
(2) The invention constructs the bacillus licheniformis recombinant strain BLM2 for expressing the fucosyltransferase HM3, and 2' -FL of 2.91g/L can be obtained after the recombinant strain BLM2 is fermented for 36 hours in a shaking way under the culture condition of 42 ℃; 2' -FL output reaches 56g/L after the recombinant bacteria BLM2 is fed-batch fermented for 46h in a 30L fermentation tank, and the maximum OD 600 72.1.
Drawings
Fig. 1: recombinant plasmid pHY-H123 plasmid map.
Fig. 2: recombinant plasmid pHT-M45 plasmid map.
Fig. 3: an electropherogram of recombinant plasmid verification; m, standard molecular weight Marker; lane 1, pHY-H123 was double digested with SmaI and EcoRI; lane 2, pHT-M45 was cut with EcoRV; lanes 3-10, transformant colonies PCR validated samples.
Fig. 4: protein electrophoresis detection of recombinant fucosyltransferase HM3 pure enzyme; m, standard protein molecular weight Marker; lane 1, recombinant fucosyltransferase HM3 pure enzyme.
Fig. 5: enzyme activity of recombinant fucosyltransferase HM3 pure enzyme under different temperature conditions.
Fig. 6: HPLC quantitative analysis of 2' -FL in fermentation supernatant.
Detailed Description
The strains and primers referred to in the examples below.
TABLE 1 strains involved in the invention
TABLE 2 primer sequences for introduction of cleavage sites
TABLE 3 primer sequences
The gene sequences used in the invention are all synthesized artificially.
The detection method and the calculation method related by the invention are as follows:
the enzyme activity detection method comprises the following steps: the reaction system was 20. Mu.L containing 0.5. Mu. Mol/L substrate GDP-fucose, 20mmol/L MnCI 2 1% Triton X-100, 50mmol/L of arsinic acid salt-hydrochloric acid buffer (pH 5.8), 0.5nmol/L of benzene-. Beta. -D-galactose, and recombinant bacterium cell disruption supernatant (containing 0.5mg of total protein) were added in a total volume of 100. Mu.L. Protein concentration was determined by the Bradeford method using the Bio-Rad protein assay kit with BSA as the standard protein. After incubating the mixture at 37℃for 1 hour, the reaction was terminated with 300. Mu.L of chloroform/methanol (2:1, v/v), and after mixing, the mixture was centrifuged at 12000rpm for 3 minutes, and the supernatant was subjected to HPLC detection, whereby the enzyme activity of fucosyltransferase HM3 in the disrupted supernatant of the recombinant cell was calculated by detecting the amount of the product produced in the reaction system by HPLC. The enzyme activity was defined as the amount of enzyme required to produce 1pmol of product under the set reaction conditions for 1h was 1U.
HPLC detection 2' -FL:
the sample treatment method comprises the following steps:
1. fermenting liquor 12000r/min, centrifuging for 20min,
2. 500ul of supernatant is taken, absolute ethanol with the final concentration of 70 percent is added, the temperature is minus 20 ℃ for 2 hours,
3. and then 12000r/min, centrifuging for 20min, and taking 200ul of supernatant, and placing the supernatant into a liquid phase sample injection bottle.
Chromatography column Dikma CarboPac Ca2 +300X8.0 mm,6 μm (Cat. No: 99304) mobile phase: water flow rate: 1.0mL/min detector: RI column temperature: 80℃sample injection amount: 10. Mu.L.
Protein concentration detection:
protein content determination reference coomassie brilliant blue dye solution method: adding 40 μl of sample to be tested into 200 μl of coomassie brilliant blue solution, slowly mixing, standing for 5min, detecting the absorbance at 595nm, and measuring the absorbance at 595nm according to protein concentration standard curve y= 0.2215x-0.0006 (x is absorbance at 595nm, y is protein concentration mg·mL) -1 ,R 2 =0.9975) calculates the protein concentration in the sample.
Calculation of specific enzyme Activity (U/mg):
the enzyme activity (U) per ml of sample solution was divided by its protein concentration (mg).
EXAMPLE 1 determination of the fucosyltransferase Gene sequence
Comparing infant intestinal metagenome collected in tin-free city with CAZyme database by using dbCAN2 comparison tool, screening and comparing to obtain the gene sequence of family 1 glycotransferase (GT 1), screening out fucosyltransferase gene with strong structural stability by using protein primary structure simulation prediction (ExpASY-ProtParam), secondary structure simulation prediction (SOPMA) and three-dimensional structure template prediction (SWISS-MODEL), artificially synthesizing the gene fragment, named HM3, and carrying out heterologous expression and activity test.
In particular, P is obtained by homologous recombination Lan The promoter (shown as a nucleotide sequence SEQ ID NO. 3) and a terminator ter (shown as a nucleotide sequence SEQ ID NO. 4) of the xylose isomerase gene are cloned to a vector pHY300-PLK respectively together with a nucleotide sequence (shown as a nucleotide sequence SEQ ID NO. 2) for encoding fucosyltransferase HM3, so as to obtain a recombinant plasmid pHY-HM3.
The specific method for constructing the recombinant plasmid pHY-HM3 comprises the following steps: first, using Bacillus licheniformis genome as a template, amplifying P by using a primer pair PF11-F/R Lan Promoter sequence, terminator sequence was amplified using primer pair PF13-F/RA column; the nucleotide sequence shown in SEQ ID NO.2 synthesized chemically is used as a template, and a primer pair PF12-F/R is used for amplifying the HM3 coding gene sequence. Then, the three fragments were once ligated to pHY300-PLK, which had been tangential using HindIII and BamHI enzymes, by homologous recombination to transform E.coli, and positive transformants were picked up and plasmids were extracted to obtain recombinant plasmid pHY-HM3.
The recombinant plasmid pHY-HM3 was transformed into Bacillus licheniformis ATCC 9945A to obtain recombinant bacterial BHM3. Culturing recombinant strain on LB plate, culturing at 37deg.C for 16 hr, picking single colony, inoculating into 15mL LB culture medium at 37deg.C for 250 r.min -1 Culturing for 16-18 h as seed solution, transferring 1mL of seed solution into 30mL of shake flask fermentation medium, controlling initial OD to 0.5-1, and culturing at 37deg.C or 42deg.C and 250r.min -1 Culturing. Fermenting for 48h, collecting cells, ultrasonic crushing to obtain crude enzyme solution, and detecting the enzyme activity of fucosyltransferase in the supernatant of the crushed solution. The result shows that the enzyme activity in the supernatant of the recombinant BHM3 cell disruption solution is 11.2U/mL.
EXAMPLE 2 cloning of fucosyltransferase HM3 and construction of 2' -FL-producing recombinant bacterium
The nucleotide sequence of SEQ ID NO.2 was first chemically synthesized, and the recombinant plasmid pHY-HM3 was obtained in the same manner as in example 1.
Then P is subjected to homologous recombination Lan The promoter (nucleotide sequence SEQ ID NO. 3) and terminator ter (nucleotide sequence SEQ ID NO. 4) of xylose isomerase gene were ligated to vector pHY300-PLK, respectively, with mannose mutase gene manB (nucleotide sequence SEQ ID NO. 5), mannose-1-phosphate-guanylate transferase gene manC (nucleotide sequence SEQ ID NO. 6), GDP-mannose-4, 6-dehydratase gene gmd (nucleotide sequence SEQ ID NO. 7), GDP-L-fucose synthase gene wcaG (nucleotide sequence SEQ ID NO. 8) to construct plasmid pHY-manB, pHY-manC, pHY-gmd, pHY-wcaG containing 4 expression cassettes.
The construction method of the recombinant plasmid is as follows:
taking the construction method of the recombinant plasmid pHY-manB as an example: p was amplified separately by the same method as in example 1 Lan PromotersSequence and ter terminator sequence; amplifying a manB coding gene sequence by using a nucleotide sequence shown in a chemically synthesized SEQ ID NO.5 as a template and using a primer pair PF42-F/R, then connecting the three fragments to pHY300-PLK which is tangentially treated by using HindIII and BamHI double enzymes at one time through homologous recombination, transforming escherichia coli, picking up positive transformants, extracting plasmids, and obtaining a recombinant plasmid pHY-manB.
The nucleotide sequence shown in SEQ ID No.6 synthesized chemically is used as a template, a primer pair PF52-F/R is used for amplifying a manC coding gene sequence, and the gene sequence is connected with a plasmid subjected to corresponding double enzyme digestion by the same method, so that a recombinant plasmid pHY-manC is obtained. The nucleotide sequence shown in SEQ ID No.7 synthesized chemically is used as a template, a primer pair PF62-F/R is used for amplifying the gmd coding gene sequence, and the gene sequence is connected with the plasmid subjected to corresponding double enzyme digestion by the same method to obtain the recombinant plasmid pHY-gmd. The nucleotide sequence shown in SEQ ID No.8 synthesized chemically is used as a template, a primer pair PF72-F/R is used for amplifying the wcaG coding gene sequence, and the gene sequence is connected with the plasmid after the corresponding double enzyme digestion by the same method, so as to obtain the recombinant plasmid pHY-wcaG.
Amplifying the P1 by using the recombinant plasmid pHY-manB as a template and using a primer pair to obtain the recombinant plasmid pHY-manB containing the enzyme cutting sites Lan The expression cassette fragments of the promoter, the manB gene and the ter terminator are designated H1. The same method is used, pHY-manC, pHY-gmd, pHY-wcaG and pHY-HM3 are respectively used as templates, and the primer pair P2-P5 is used for respectively amplifying to obtain corresponding expression cassette fragments which are respectively named as H2, H3, H4 and M5. The reaction conditions are as follows: after pre-denaturation at 95 ℃ for 5min, the mixture enters the next cycle of denaturation at 94 ℃ for 30s, annealing at 54 ℃ for 30s, and extension at 72 ℃ for 40s for 30 cycles; extending at 72 ℃ for 10min, and preserving heat at 4 ℃. The gene expression fragments H1, H2 and H3 are connected into pHY300PLK plasmid by homologous recombination to obtain recombinant plasmid pHY-H123 (figure 1). And then the gene expression fragments H4 and M5 are connected into pHT43 plasmid by utilizing a homologous recombination method in sequence to obtain recombinant plasmid pHT-M45 (figure 2). The construction of the plasmid was further verified by 1% agarose gel electrophoresis (FIG. 3).
The successfully constructed recombinant plasmid pHYH123 was transformed according to Li, Y; jin, k; zhang, LA third party; ding, z.; gu, z.; bacillus licheniformis ATCC 9945A was transformed by the method of Shi, G.development of an Inducible Secretory Expression System in Bacillus licheniformis Based on an Engineered Xylose OPERon. Journal ofAgricultural and Food Chemistry 2018,66,9456-9464 to obtain Bacillus licheniformis engineering strain BLH1. The specific transformation method comprises the following steps: fresh single colonies of Bacillus licheniformis were first picked and inoculated into 50mL LBSP medium (10 g.L -1 Peptone, 10 g.L -1 Sodium chloride, 5 g.L -1 Yeast paste, 0.50 mol.L -1 Sorbitol), at 37℃at 200rpm for 12h. Next, 0.4mL of the culture medium was transferred to 50mL of LBS medium, and cultured at 37℃and 200rpm until the cell concentration reached an absorbance (OD) of 600nm 600 ) 0.6 to 0.8, and collecting the bacterial cells by freeze centrifugation (3000 g,8 min). With 20mL SHMP medium (0.5 mol.L) -1 Sorbitol, 0.5 mol.L -1 Mannitol, 10% glycerol) and then freeze-centrifuging to discard the supernatant to wash the cells, for a total of 4 washes. After completion, the somatic cells were resuspended in 1mL SHMP medium, 90. Mu.L was removed and placed in a 1.5mL centrifuge tube, about 200ng of plasmid was added thereto, and the mixture was gently mixed and then ice-cooled for 5min. Transferring the mixture into a precooled electrorotating cup, and placing the electrorotating cup into an electrorotating instrument to carry out electroporation, wherein the conditions are as follows: voltage, 1000V; time, 5ms. 800. Mu.L LBSPG medium (10 g.L) -1 Peptone, 10 g.L -1 Sodium chloride, 5 g.L -1 Yeast paste, 0.50 mol.L -1 Sorbitol, 0.38 mol.L -1 Mannitol) and gently mixed, incubated at 37℃for 2h at 100rpm, plated on a resistance plate and incubated at 37 ℃.
And then the recombinant plasmid pHT-M45 is transformed into Bacillus licheniformis engineering bacteria BLH1 by the same method to obtain recombinant Bacillus licheniformis bacteria BLM2.
Example 32' -FL shaking flask fermentation
Streaking and activating the bacillus licheniformis engineering bacteria BLM2 constructed in the example 2 on an LB plate, culturing for 16 hours at 37 ℃, picking single colony, inoculating the single colony into 15mL LB culture medium at 37 ℃ and 250 r.min -1 Culturing for 16-18 h as seed solution, transferring 1mL of seed solution into 30mL of shake flask fermentation medium, and shake flask fermentingThe initial OD is controlled to be 0.5-1, and the temperature is 37 ℃ or 42 ℃ and the temperature is 250 r.min -1 Culturing. Sampling every 12h, fermenting at 4deg.C for 12000 r.min -1 Centrifugation was carried out for 10min under conditions and the supernatant was used to detect the product (FIG. 4). The results show that 2.91 g/L2 '-FL can be obtained after fermentation of engineering bacterium BLM2 for 36h under the culture condition of 42 ℃, and the yield of 2' -FL in the fermentation broth for 36h at 37 ℃ is 2.83g/L.
EXAMPLE 4 characterization of enzymatic Properties
(1) Cell disruption of recombinant bacteria culture medium
The recombinant strain BLM2 was fermented using a shake flask fermentation medium at 37℃and 250rpm for 48 hours. After the fermentation broth was centrifuged at 12000rpm for 10min, the supernatant was discarded to collect the cells. Disrupted cell solution A (10 mM sodium phosphate buffer solution (pH=7.0) +0.5 mol.L) was used -1 NaCl+3g·L -1 Lysozyme) was washed, repeated 3 times, and the cells were still diluted to OD with solution a 600 Incubation was carried out at 37℃for 1-1.5h until flocculent precipitate formation was observed, and cell disruption was carried out by placing the cells on ice under conditions such that each 1 second of operation was stopped for 2 seconds and the total disruption time was 8min. And after the liquid is clarified, the crushing is successful. The resulting cell disruption solution was centrifuged at 12000rpm for 10 min.
(2) Separation and purification of recombinant fucosyltransferase HM3
The purification mode adopts Mag-beams His-Tag protein purification magnetic Beads for purification. Every 15mL centrifuge tube contains 2-3mL of protein purification magnetic beads and is equipped with a magnetic rack. The relevant operation steps are as follows: (1) regenerating magnetic beads: add 5mL ddH 2 O, mixing uniformly and magnetically separating; adding 5mL of regeneration buffer solution, uniformly mixing, and magnetically separating for 2 times; add 5mL ddH 2 O, mixing uniformly, rotating for 5min at room temperature, and magnetically separating for 2 times; add 5mLNi 2+ Regenerating buffer solution, uniformly mixing for 20min at room temperature, and magnetically separating; add 5mL ddH 2 O, mixing evenly, and carrying out magnetic separation operation for 4 times. (2) Pretreatment of magnetic beads: adding 5mL of binding buffer solution, uniformly mixing, and magnetically separating for 2 times; (3) binding of the protein of interest to the magnetic beads: adding 2mg of protein sample into the pretreated centrifuge tube, placing the centrifuge tube on a vortex oscillator to oscillate for 15s, and placing the centrifuge tube into a rotary mixer after fully and uniformly mixingAnd (3) placing the sample on a synthesizer at room temperature for 20-30min to ensure the full combination of the target protein and the magnetic beads, and performing magnetic separation after finishing. (4) Washing magnetic beads: after 10mL of wash buffer was added and gently turned over, the mixture was magnetically separated, and the mixture was twice subjected to a double operation, and the decanted mixture was collected. The purpose is as follows: washing off the impurity proteins and unbound proteins. To avoid nonspecific adsorption of proteins on the walls of the original centrifuge tube, the beads can be transferred to a new centrifuge tube. (5) Eluting target protein: 5-8mL of elution buffer was added, the magnetic separation was performed 3 times, and the decanted liquid was collected. (6) Post-treatment of magnetic beads: adding 5mL of water, and magnetically separating for 2 times; adding 5mL of the magnetic bead preservation solution, and preserving in a refrigerator at 4 ℃. The purified enzyme solution is collected, transferred to a dialysis bag with proper size and pretreatment, imidazole and salt are removed by overnight dialysis, the dialysis solution is replaced for 2-3 times, and the protein concentration is measured after the completion. If necessary, the enzyme solution may be subjected to ultrafiltration concentration.
(3) Specific enzyme activity determination of recombinant fucosyltransferase HM3
The purified recombinant fucosyltransferase HM3 purified enzyme was reacted in a reaction system of 20. Mu.L containing 0.5. Mu. Mol/L substrate GDP-fucose and 20mmol/LMnCI 2 1% Triton X-100, 50mmol/L of arsinic acid salt-hydrochloric acid buffer (pH 5.8), 0.5nmol/L of benzene-beta-D-galactose and 0.5mg of recombinant fucosyltransferase HM3 pure enzyme, the total volume was 100. Mu.L, after incubating the mixture at 37℃for 1 hour, the reaction was terminated with 300. Mu.L of chloroform/methanol (2:1, v/v), after mixing evenly, centrifugation was carried out at 12000rpm for 3 minutes, the supernatant was taken for HPLC detection, and the enzyme activity of recombinant fucosyltransferase HM3 was calculated indirectly by detecting the production amount of the product in the reaction system by HPLC, and the specific enzyme activity was calculated. The results showed that the specific enzyme activity of the recombinant fucosyltransferase HM3 pure enzyme was 50.9U/mg.
(4) Characterization of temperature characteristics of recombinant fucosyltransferase HM3
Referring to the above method for enzyme activity detection reaction, the purified recombinant fucosyltransferase HM3 purified enzyme was reacted at 30℃at 37℃at 42℃and at 50℃respectively. After the reaction, the enzyme activity of the recombinant fucosyltransferase HM3 was calculated indirectly by detecting the decrease in the substrate and the product formation in the reaction system by HPLC. The results showed that the enzyme activity at 42℃reached 141.8U/mL, which is 1.4 times that at 37℃and that the enzyme activity at 50℃was also higher than 37 ℃.
EXAMPLE 5 engineering bacterium BLM2 fermentation production of 2' -FL in 20L fermenter
Activating the Bacillus licheniformis engineering bacteria BLM2 constructed in the example 2, culturing at 37 ℃ for 16 hours, picking single colony, inoculating in 15mL LB culture medium at 37 ℃ for 250 r.min -1 Culturing for 16-18 h as seed solution, transferring 1mL of seed solution into 30mL of shake flask fermentation medium, controlling initial OD to be 0.5-1, and performing fed-batch fermentation in a fermentation tank at a fermentation temperature of 42 ℃ and an initial pH of 7.5. When the pH in the fermentation process is reduced to 7.0, the pH in the fermentation process is maintained at about 7.0 by adding 50% ammonia water, the aeration rate in the fermentation process is controlled at 0.5vvm, the DO is controlled at about 30% by coupling stirring and DO, and the upper limit of the rotating speed is set at 800rpm. After 8h fermentation, a 50% sucrose solution was continuously fed at a rate of 20mL/h, maintaining it unconsumed.
Fermentation medium: 30g/L cottonseed protein, 75g/L sucrose, 80g/L, K lactose 2 HPO 4 ·3H 2 O 9.12g/L、KH 2 PO 4 1.36g/L、FeCl 3 0.5 g/L、(NH 4 ) 2 HPO 4 10g/L (pH 7.5). 30L of fermentation tank liquid amount is 15L. The 2' -FL yield after 46h of fed-batch fermentation on a fermenter scale reached 56g/L, maximum OD 600 72.1.
Comparative example 1:
specific embodiment the same as in example 2 except that the fucosyltransferase gene HM3 was replaced with fucosyltransferase futC (GenBank: ABO 61750.1) derived from helicobacter pylori (Helicobacter pylori), and the recombinant bacteria thus constructed were fermented by the fermentation methods shown in example 3 and example 5 at 42℃and the production amount of 2' -FL by shake flask fermentation was 1.02g/L; the 2' -FL yield of the 20L fermenter fermentation was 23g/L.
Comparative example 2:
specific embodiment the same as in example 2 except that the fucosyltransferase gene HM3 was changed to fucosyltransferase wbgL (GenBank: ADN 43847.1) derived from E.coli (Escherichia coli O126), and the recombinant bacteria thus constructed were fermented by the fermentation methods shown in examples 3 and 5 at 42℃and the production yield of 2' -FL by shake flask fermentation was 0.82g/L; the 2' -FL yield of the 20L fermenter fermentation was 17g/L.
While the invention has been described with reference to the preferred embodiments, it is not limited thereto, and various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (10)
1. The fucosyltransferase is characterized in that the amino acid sequence of the fucosyltransferase is shown in SEQ ID NO. 1.
2. A gene encoding the fucosyltransferase of claim 1, wherein the nucleotide sequence of the gene is shown in SEQ ID No. 2.
3. A recombinant bacterium for expressing a fucosyltransferase according to claim 1, wherein the fucosyltransferase is expressed in a bacterium or yeast.
4. The recombinant bacterium of claim 3, wherein the host is bacillus licheniformis.
5. A method of constructing the recombinant bacterium of claim 3 or 4, comprising the steps of:
(1) Respectively fusing a promoter shown in SEQ ID NO.3 and a terminator shown in SEQ ID NO.4 at two ends of a phosphomannose mutase gene manB, a mannose-1-phosphate-guanylate transferase gene manC, a GDP-mannose-4, 6-dehydratase gene gmd, a GDP-L-fucose synthase gene wcaG and a fucosyltransferase gene to obtain an expression fragment containing the genes;
(2) Connecting the expression fragment constructed in the step (1) to a plasmid pHY300PLK in the sequence of manB, manC and gmd to obtain a recombinant plasmid 1; then the gene wcaG and the gene of claim 2 are connected to plasmid pHT43 to obtain recombinant plasmid 2;
(3) And (3) converting the recombinant plasmid 1 and the recombinant plasmid 2 constructed in the step (2) into bacillus licheniformis to obtain recombinant bacillus licheniformis.
6. A method for producing 2' -fucosyllactose, characterized in that the recombinant bacterium of claim 3 or 4 is used for fermentation at 37 ℃ to 42 ℃ for at least 46 hours.
7. The method according to claim 6, wherein the medium for fermentation comprises: cottonseed protein 5-30g/L, sucrose 40-75g/L, lactose 40-80g/L, K 2 HPO 4 ·3H 2 O7.28-9.12g/L、KH 2 PO 4 1.36-3.15g/L、FeCl 3 0.5-1g/L and (NH) 4 ) 2 HPO 4 5-10g/L; the initial pH is 6.5-7.5.
8. The method of claim 7, wherein the fermentation process is further fed with sucrose after 6-10 hours of fermentation.
9. Use of a fucosyltransferase according to claim 1, or a gene according to claim 2, or a recombinant bacterium according to claim 3 or 4, or a method according to claim 5, or a method according to any one of claims 6-8 for the production of 2 '-fucosyllactose and products containing 2' -fucosyllactose.
10. The use according to claim 9, wherein the product comprises an infant formula.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310567618.5A CN117187206A (en) | 2023-05-19 | 2023-05-19 | Fucosyltransferase from intestinal microorganisms and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310567618.5A CN117187206A (en) | 2023-05-19 | 2023-05-19 | Fucosyltransferase from intestinal microorganisms and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117187206A true CN117187206A (en) | 2023-12-08 |
Family
ID=88989447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310567618.5A Pending CN117187206A (en) | 2023-05-19 | 2023-05-19 | Fucosyltransferase from intestinal microorganisms and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117187206A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130217068A1 (en) * | 2010-10-11 | 2013-08-22 | Jennewein Biotechnologie Gmbh | Novel fucosyltransferases and their applications |
US20200181665A1 (en) * | 2017-07-07 | 2020-06-11 | Jennewein Biotechnologie Gmbh | Fucosyltransferases and their use in producing fucosylated oligosaccharides |
CN115838682A (en) * | 2022-12-01 | 2023-03-24 | 南京诺云生物科技有限公司 | Bacillus licheniformis engineering strain for efficiently producing 2' -fucosyllactose by utilizing mannan |
CN115948314A (en) * | 2022-12-01 | 2023-04-11 | 无锡特殊食品与营养健康研究院有限公司 | Bacillus licheniformis engineering strain for efficiently producing 2' -fucosyllactose |
-
2023
- 2023-05-19 CN CN202310567618.5A patent/CN117187206A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130217068A1 (en) * | 2010-10-11 | 2013-08-22 | Jennewein Biotechnologie Gmbh | Novel fucosyltransferases and their applications |
US20200181665A1 (en) * | 2017-07-07 | 2020-06-11 | Jennewein Biotechnologie Gmbh | Fucosyltransferases and their use in producing fucosylated oligosaccharides |
CN115838682A (en) * | 2022-12-01 | 2023-03-24 | 南京诺云生物科技有限公司 | Bacillus licheniformis engineering strain for efficiently producing 2' -fucosyllactose by utilizing mannan |
CN115948314A (en) * | 2022-12-01 | 2023-04-11 | 无锡特殊食品与营养健康研究院有限公司 | Bacillus licheniformis engineering strain for efficiently producing 2' -fucosyllactose |
Non-Patent Citations (2)
Title |
---|
""MULTISPECIES: glycosyltransferase family 10 [Akkermansia]",WP_102728057.1", 《GENBANK》, 26 May 2022 (2022-05-26), pages 1 - 2 * |
ZHENGHAI XU等: "Structure-function analysis of human alpha1, 3-fucosyltransferase. Amino acids involved in acceptor substrate specificity", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 271, no. 15, 12 April 1996 (1996-04-12), pages 1 - 3 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102869783B (en) | Psicose-epimerization enzyme immobilizatio and use described psicose-epimerase to prepare the method for D-Psicose | |
CN114480240A (en) | Genetic engineering bacterium for producing fucosyllactose and production method thereof | |
CN111548979B (en) | Recombinant escherichia coli for synthesizing lactoyl N-neotetraose and construction method and application thereof | |
CN114874964B (en) | Construction method and application of recombinant escherichia coli for high yield of 2' -fucosyllactose | |
CN112251428B (en) | Glutamic acid decarboxylase mutant and application thereof in production of gamma-aminobutyric acid | |
CN112126615B (en) | Butyric acid producing bacillus subtilis and construction method and application thereof | |
CN111748535A (en) | Alanine dehydrogenase mutant and application thereof in fermentation production of L-alanine | |
DK202170250A1 (en) | Identification of an a-1,2-fucosyltransferase for the in vivo production of pure lnfp-i | |
CN115948314B (en) | Bacillus licheniformis engineering strain for efficiently producing 2' -fucosyllactose | |
CN111411066A (en) | Double-way composite neuraminic acid-producing bacillus subtilis and construction method thereof | |
CN115838682A (en) | Bacillus licheniformis engineering strain for efficiently producing 2' -fucosyllactose by utilizing mannan | |
CN115725484A (en) | Enzyme mutation expression engineering bacterium for synthesizing D-psicose and application thereof | |
CN116200318A (en) | Recombinant bacillus subtilis for exocrine expression of D-psicose 3-epimerase | |
CN117187206A (en) | Fucosyltransferase from intestinal microorganisms and application thereof | |
CN116640740A (en) | Fucosyltransferase from intestinal microorganisms and application thereof | |
CN116676287A (en) | Fucosyltransferase from intestinal microorganisms and application thereof | |
CN114806991A (en) | Engineering escherichia coli for improving yield of fucosyllactose and production method | |
CN116917485A (en) | Recombinant microorganism expressing fucosyltransferase and method for producing 2' -fucosyllactose using the same | |
CN109370969B (en) | Application of recombinant Klebsiella in preparation of 1, 3-propylene glycol | |
CN113528495A (en) | Bacillus subtilis for stably expressing chitobiose deacetylase and construction method and application thereof | |
CN115261367B (en) | Cellobiose epimerase mutant and application thereof | |
CN116042562B (en) | Recombinant saccharomycetes and application thereof | |
CN116200360B (en) | FutCB mutant and method for biosynthesis of 2' -fucosyllactose | |
CN111607548B (en) | Recombinant escherichia coli for producing mannan and application thereof | |
CN114686500B (en) | 1, 4-alpha-glucan branching enzyme, coding gene, engineering strain and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |